<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">World Allergy Organ J</journal-id><journal-id journal-id-type="iso-abbrev">World Allergy Organ J</journal-id><journal-id journal-id-type="publisher-id">wox</journal-id><journal-title-group><journal-title>The World Allergy Organization Journal</journal-title></journal-title-group><issn pub-type="epub">1939-4551</issn><publisher><publisher-name>World Allergy Organization Journal</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">3513111</article-id><article-id pub-id-type="doi">10.1097/01.WOX.0000411914.12461.9e</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstracts of the XXII World Allergy Congress</subject></subj-group><subj-group subj-group-type="heading"><subject>Oral Abstract Session</subject></subj-group><series-title>Sublingual Immunotherapy 1</series-title></article-categories><title-group><article-title>157&#x02003;The Post-Treatment Efficacy of House Dust Mite Sublingual Allergen Immunotherapy Tablets in Adults With Allergic Rhinitis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bergmann</surname><given-names>Karl-Christian</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Demoly</surname><given-names>Pascal</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Worm</surname><given-names>Margitta</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Fokkens</surname><given-names>Wystke</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Anna</surname><given-names>Tabar</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Helene</surname><given-names>Nguyen</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>de Beaumont</surname><given-names>Olivier</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Melac</surname><given-names>Michel</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Frereux</surname><given-names>Marine</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Zeldin</surname><given-names>Robert K</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Allergy-Centre-Charit&#x000e9;, Charit&#x000e9; - Universit&#x000e4;tsmedizin Berlin, Berlin, Germany</aff><aff id="aff2"><label>2</label>Allergy, University Hospital of Montpellier, Montpellier, France</aff><aff id="aff3"><label>3</label>Dermatology, Charite University Clinic, Berlin, Germany</aff><aff id="aff4"><label>4</label>Department of Otorhinolaryngology, AMC, Amsterdam, Netherlands</aff><aff id="aff5"><label>5</label>Department of Allergy, Complejo Hospitalario de Navarra, Pamplona, Spain</aff><aff id="aff6"><label>6</label>Stallergenes SA, Antony, France.</aff><pub-date pub-type="epub"><day>17</day><month>2</month><year>2012</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2012</year></pub-date><volume>5</volume><issue>Suppl 2</issue><issue-title>Abstracts of the XXII World Allergy Congress, 4&#x02013;8 December, 2012 Canc&#x000fa;n, M&#x000e9;xico</issue-title><fpage seq="a">S69</fpage><lpage>S69</lpage><permissions><copyright-statement>Copyright &#x000a9; 2012 by World Allergy Organization</copyright-statement><copyright-year>2012</copyright-year></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="waoj-5-S69.pdf"/><abstract><sec><title>Background</title><p>The efficacy and safety of 2 doses of sublingual allergen immunotherapy house dust mite (HDM) tablets administered for 12 months were demonstrated in a randomized, double-blind, placebo-controlled study of adults suffering from HDM-related allergic rhinitis. Here we report the efficacy during the 12-month, treatment-free, follow-up period.</p></sec><sec><title>Methods</title><p>Of the 509 patients randomized, 412 were included in the year 2 full analysis set (500 IR = 132, 300 IR = 134, Placebo = 146). The primary efficacy variable was the Average Adjusted Symptom Score (AAdSS, scale 0&#x02013;12) an average of the daily score based on the severity of 4 rhinitis symptoms (sneezing, rhinorrhea, nasal pruritus and nasal congestion) and adjusted for rescue medication usage. The AAdSS was analyzed, at the end of the post-treatment period, using an ANCOVA and at 3, 6, 8 and 12 months after treatment cessation in a secondary analysis, using repeated measures ANCOVA.</p></sec><sec><title>Results</title><p>At the end of the post-treatment period, the 500 IR group showed a significant improvement in AAdSS vs. placebo (<italic>P</italic> = 0.021) with a LS Means difference of &#x02013;0.70 (95% CI [&#x02013;1.29, &#x02013;0.11]), corresponding to &#x02013;19.1%. The LS Means difference of &#x02013;0.62 (95% CI [&#x02013;1.20, &#x02013;0.05]) between the 300 IR and placebo groups was also significant (<italic>P</italic> = 0.034), corresponding to &#x02013;17.0%. The difference between the active treatment groups was not statistically significant. Eight months after treatment cessation, which corresponds to the autumn peak in HDM, the relative LS mean difference was &#x02013;20.9% (<italic>P</italic> = 0.0079) for the 500 IR and was &#x02013;25.5% (<italic>P</italic> = 0.0011) for the 300 IR group.</p></sec><sec><title>Conclusions</title><p>During the 12-month post-treatment period, house dust mite sublingual immunotherapy tablets at doses of 500 IR and 300 IR provided sustained symptom relief, demonstrating their efficacy after treatment cessation.</p></sec></abstract></article-meta></front></article>